Literature DB >> 22293167

Liver function testing with nuclear medicine techniques is coming of age.

Roelof J Bennink1, Mark Tulchinsky, Wilmar de Graaf, Zakiyah Kadry, Thomas M van Gulik.   

Abstract

Liver function is a broad term, as the organ participates in a multitude of different physiological and biochemical processes, including metabolic, synthetic, and detoxifying functions. However, it is the function of the hepatocyte that is central to sustaining normal life and dealing with disease states. When the liver begins to fail in severely ill patients, it forecasts a terminal outcome. However, unlike the glomerular filtration rate which clearly quantifies the key renal function, at most practice sites, there is no clinically available quantitative test for liver function. Although it is commonplace to assess indirect evidence of that function (by measuring blood levels of its end products and by-products) and to detect an acute injury (by following rising transaminases), a widely available test that would directly measure hepatocellular function is lacking. This article reviews current knowledge on liver function studies and focuses on those nuclear medicine tests available to study the whole liver and regional liver function. The clinical application driving these tests, prediction of remnant liver function after partial hepatectomy for primary liver malignancy or metastatic disease, is addressed here in detail. The test was recently validated for this specific application and was shown to be better than the current standard of practice (computed tomography volumetry), particularly in patients with hepatic comorbidities like cirrhosis, steatosis, or cholestasis. Furthermore, early assessment of regional liver function increase after preoperative portal vein embolization becomes possible with this technology. The limiting factor to a wider acceptance of this test is based on the lack of clinical software that would allow calculation of liver function parameters. This article provides information that enables a clinical nuclear medicine facility to provide this test using readily available equipment. Furthermore, it addresses emerging clinical applications that are under investigation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22293167     DOI: 10.1053/j.semnuclmed.2011.10.003

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  13 in total

1.  Is it time to standardize patient factors for HPB surgery?

Authors:  Saxon Connor
Journal:  HPB (Oxford)       Date:  2014-10       Impact factor: 3.647

2.  Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection.

Authors:  Kasia P Cieslak; Roelof J Bennink; Wilmar de Graaf; Krijn P van Lienden; Marc G Besselink; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2016-07-25       Impact factor: 3.647

3.  The combination of indocyanine green clearance test and model for end-stage liver disease score predicts early graft outcome after liver transplantation.

Authors:  Tang Yunhua; Ju Weiqiang; Chen Maogen; Yang Sai; Zhang Zhiheng; Wang Dongping; Guo Zhiyong; He Xiaoshun
Journal:  J Clin Monit Comput       Date:  2017-08-22       Impact factor: 2.502

4.  Imaging-based evaluation of liver function: comparison of ⁹⁹mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI.

Authors:  Dominik Geisel; Lutz Lüdemann; Vera Fröling; Maciej Malinowski; Martin Stockmann; Annekathrin Baron; Bernhard Gebauer; Daniel Seehofer; Vikas Prasad; Timm Denecke
Journal:  Eur Radiol       Date:  2014-12-02       Impact factor: 5.315

5.  Donor Indocyanine Green Clearance Test Predicts Graft Quality and Early Graft Prognosis After Liver Transplantation.

Authors:  Yunhua Tang; Ming Han; Maogen Chen; Xiaoping Wang; Fei Ji; Qiang Zhao; Zhiheng Zhang; Weiqiang Ju; Dongping Wang; Zhiyong Guo; Xiaoshun He
Journal:  Dig Dis Sci       Date:  2017-09-20       Impact factor: 3.199

Review 6.  Optimization of the future remnant liver: review of the current strategies in Europe.

Authors:  Riccardo Memeo; Maria Conticchio; Emmanuel Deshayes; Silvio Nadalin; Astrid Herrero; Boris Guiu; Fabrizio Panaro
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

7.  Development of ⁶⁸Ga-labelled DTPA galactosyl human serum albumin for liver function imaging.

Authors:  Roland Haubner; David R Vera; Salman Farshchi-Heydari; Anna Helbok; Christine Rangger; Daniel Putzer; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-12       Impact factor: 9.236

8.  Monitoring of Total and Regional Liver Function after SIRT.

Authors:  Roelof J Bennink; Kasia P Cieslak; Otto M van Delden; Krijn P van Lienden; Heinz-Josef Klümpen; Peter L Jansen; Thomas M van Gulik
Journal:  Front Oncol       Date:  2014-06-16       Impact factor: 6.244

9.  [68Ga]NOTA-Galactosyl Human Serum Albumin: a Tracer for Liver Function Imaging with Improved Stability.

Authors:  Roland Haubner; Andreas M Schmid; Andreas Maurer; Christine Rangger; Llanos Geraldo Roig; Bernd J Pichler; Irene J Virgolini
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

10.  Three-Dimensional Quantitative Evaluation of the Segmental Functional Reserve in the Cirrhotic Liver Using Multi-Modality Imaging.

Authors:  Canhong Xiang; Yingmao Chen; Mingzhe Shao; Can Li; Xin Huang; Lei Gong; Ang Li; Weidong Duan; Aiqun Zhang; Jiahong Dong
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.